Agios Pharmaceuticals AGIO Interest Expense
Interest Expense at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's interest expense.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's interest expense?
- Agios Pharmaceuticals (AGIO) reported interest expense of $10.8M in Q1 2026.
- How has Agios Pharmaceuticals's interest expense changed year-over-year?
- Agios Pharmaceuticals's interest expense decreased by 32.9% year-over-year, from $16.09M to $10.8M.
- What is the long-term trend for Agios Pharmaceuticals's interest expense?
- Over 3 years (2021 to 2025), Agios Pharmaceuticals's interest expense has grown at a 307.0% compound annual growth rate (CAGR), from $836K to $56.38M.
- What does interest expense mean?
- Cost of borrowing — interest paid or accrued on bonds, bank loans, credit facilities, finance leases, and other debt obligations.